Piper Sandler initiated coverage on Viking Therapeutics
$VKTX
Biotechnology: Pharmaceutical Preparations
Health Care
Piper Sandler initiated coverage of Viking Therapeutics with a rating of Overweight
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/2/2024 | Overweight | Piper Sandler | |
| 11/22/2024 | $109.00 | Buy | B. Riley Securities |
| 11/4/2024 | $90.00 → $102.00 | Buy | H.C. Wainwright |
| 9/11/2024 | $80.00 | Overweight | JP Morgan |
| 6/27/2024 | $105.00 | Overweight | Morgan Stanley |
| 5/16/2024 | $115.00 → $116.00 | Outperform → Strong Buy | Raymond James |
| 3/26/2024 | $116.00 → $138.00 | Outperform | Oppenheimer |
| 3/7/2024 | $110.00 | Buy | Jefferies |
Conference Call Scheduled for Wednesday, February 5 at 4:30 p.m. Eastern Time SAN DIEGO, Jan. 29, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the fourth quarter and year-end 2024 after the market close on Wednesday, February 5, 2025. The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m. E
13-Week Study to Evaluate the Safety and Efficacy of Oral VK2735 Dosed Once Daily SAN DIEGO, Jan. 8, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the initiation of a Phase 2 clinical trial of the oral tablet formulation of VK2735, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. VK2375 is being developed in both oral and subcutaneous formulations for the potential treatment of various metabolic disorders such as obesity.
SAN DIEGO, Jan. 6, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will deliver a corporate presentation at the 43rd Annual J.P. Morgan Healthcare Conference. The conference will take place January 13-16, 2025, in San Francisco, California. Details are as follows: 43rd Annual J.P. Morgan Healthcare ConferenceDetails: Dr. Lian will deliver a corporate presenta
Piper Sandler initiated coverage of Viking Therapeutics with a rating of Overweight
B. Riley Securities initiated coverage of Viking Therapeutics with a rating of Buy and set a new price target of $109.00
H.C. Wainwright reiterated coverage of Viking Therapeutics with a rating of Buy and set a new price target of $102.00 from $90.00 previously
Conference Call Scheduled for Wednesday, February 5 at 4:30 p.m. Eastern Time SAN DIEGO, Jan. 29, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the fourth quarter and year-end 2024 after the market close on Wednesday, February 5, 2025. The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m. E
Third quarter performance driven by strong portfolio royalty revenue growth 2024 full year revenue guidance increased to $160 million - $165 million (previously $140 million - $157 million) and core adjusted earnings per diluted share1 increased to $5.50 - $5.70 (previously $5.00 - $5.50) Company to hold Investor and Analyst Day in Boston on December 10, 2024 Conference call begins at 8:30 a.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and nine months ended September 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8:30 a.m. Easter
Conference call scheduled for 4:30 p.m. ET today End-of-Phase 2 Meeting for Subcutaneous VK2735 for Obesity Planned for 4Q24Phase 2 Study of Oral VK2735 in Obesity Expected to Begin 4Q24Results of Phase 2b VOYAGE Study of VK2809 in NASH/MASH With Fibrosis Selected for Oral Presentation at AASLDPositive Phase 1b Results from VK0214 Study in X-ALD Demonstrate Safety, Tolerability and Reductions in Very Long-Chain Fatty Acids and Plasma LipidsStrong Quarter-End Cash Position of $930 MillionSAN DIEGO, Oct. 23, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrin
SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)
SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)
SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)
4 - Viking Therapeutics, Inc. (0001607678) (Issuer)
4 - Viking Therapeutics, Inc. (0001607678) (Issuer)
4 - Viking Therapeutics, Inc. (0001607678) (Issuer)
144 - Viking Therapeutics, Inc. (0001607678) (Subject)
144 - Viking Therapeutics, Inc. (0001607678) (Subject)
144 - Viking Therapeutics, Inc. (0001607678) (Subject)